Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2019 Filed Aug 21, 2019 20:32 UTC |
Furlow Brenda S.SVP - General Counsel
|
Tax withholdingCommon Stock | 745 | $197.57 | $147,189.65 |
DisclosureSEC source: 0000914190-19-000328 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,203 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:32 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 1,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-19-000328 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:45 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 7,410 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0000914190-19-000308 · edgar.xml · derivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,590 Underlying: Common Stock · 7,410 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:45 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 7,410 | $67.46 | $499,878.60 |
DisclosureSEC source: 0000914190-19-000308 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risk of forfeiture will lapse on August 18, 2019; (ii) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (iii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iv) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantStock Options (Right to Buy) · Derivative | 21,265 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000260 · edgar.xml · derivative · entry 16 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,265 Underlying: Common Stock · 21,265 shares Expires 2026-08-07 F10 · derivative.exercise_date: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantStock Options (Right to Buy) · Derivative | 15,948 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000260 · edgar.xml · derivative · entry 15 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,948 Underlying: Common Stock · 15,948 shares Expires 2026-08-07 F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantRestricted Stock Units · Derivative | 3,151 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000260 · edgar.xml · derivative · entry 14 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,151 Underlying: Common Stock · 3,151 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:12 UTC |
BAUMGARTNER ROBERT VDirector
|
PurchaseCommon Stock | 500 | $191.06 | $95,530.00 |
DisclosureSEC source: 0000914190-19-000261 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,726 Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 13,290 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000259 · edgar.xml · derivative · entry 16 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,290 Underlying: Common Stock · 13,290 shares Expires 2026-08-07 F10 · derivative.exercise_date: Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 9,968 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000259 · edgar.xml · derivative · entry 15 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,968 Underlying: Common Stock · 9,968 shares Expires 2026-08-07 F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 1,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000259 · edgar.xml · derivative · entry 14 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,969 Underlying: Common Stock · 1,969 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 26,581 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000258 · edgar.xml · derivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,581 Underlying: Common Stock · 26,581 shares Expires 2026-08-07 F10 · derivative.exercise_date: Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 19,936 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000258 · edgar.xml · derivative · entry 14 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,936 Underlying: Common Stock · 19,936 shares Expires 2026-08-07 F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC |
Hippel JamesChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000258 · edgar.xml · derivative · entry 13 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938 Underlying: Common Stock · 3,938 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 15,948 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000257 · edgar.xml · derivative · entry 10 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,948 Underlying: Common Stock · 15,948 shares Expires 2026-08-07 F8 · derivative.exercise_date: Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 11,961 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000257 · edgar.xml · derivative · entry 9 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,961 Underlying: Common Stock · 11,961 shares Expires 2026-08-07 F7 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantRestricted Stock Units · Derivative | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000257 · edgar.xml · derivative · entry 8 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363 Underlying: Common Stock · 2,363 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F7 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 57,150 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000256 · edgar.xml · derivative · entry 17 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,150 Underlying: Common Stock · 57,150 shares Expires 2026-08-07 F11 · derivative.exercise_date: Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 85,725 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000256 · edgar.xml · derivative · entry 16 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,725 Underlying: Common Stock · 85,725 shares Expires 2026-08-07 F10 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 16,937 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000256 · edgar.xml · derivative · entry 15 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,937 Underlying: Common Stock · 16,937 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:10 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantCommon Stock | 11,291 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000256 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,467 F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risk of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risk of forfeiture will lapse with repect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iv) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:18 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 16,969 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0001562180-19-003930 · primarydocument.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,969 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:18 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 494 | $214.07 | $105,749.69 |
DisclosureSEC source: 0001562180-19-003930 · primarydocument.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,176 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.03 to $214.21, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:18 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 9,909 | $213.32 | $2,113,768.06 |
DisclosureSEC source: 0001562180-19-003930 · primarydocument.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,670 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.00 to $213.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:18 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 6,566 | $212.75 | $1,396,910.59 |
DisclosureSEC source: 0001562180-19-003930 · primarydocument.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,579 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.285 to $212.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:18 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 16,969 | $67.46 | $1,144,728.74 |
DisclosureSEC source: 0001562180-19-003930 · primarydocument.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 20:46 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 15,037 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0001562180-19-003915 · primarydocument.xml · derivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,969 Underlying: Common Stock · 15,037 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 20:46 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 15,037 | $212.43 | $3,194,339.98 |
DisclosureSEC source: 0001562180-19-003915 · primarydocument.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,176 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.00 to $213.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 20:46 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 15,037 | $67.46 | $1,014,396.02 |
DisclosureSEC source: 0001562180-19-003915 · primarydocument.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:46 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 17,994 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0001562180-19-003915 · primarydocument.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,006 Underlying: Common Stock · 17,994 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:46 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 17,994 | $212.75 | $3,828,183.91 |
DisclosureSEC source: 0001562180-19-003915 · primarydocument.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,176 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.00 to $214.125, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:46 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 17,994 | $67.46 | $1,213,875.24 |
DisclosureSEC source: 0001562180-19-003915 · primarydocument.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:49 UTC |
Vessey RupertDirector
|
GrantStock Options (Right to buy) · Derivative | 588 | $0.00 Strike: $209.26 | $0.00 |
DisclosureSEC source: 0001562180-19-003807 · primarydocument.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 Underlying: Common Stock · 588 shares Expires 2029-10-25 F1 · derivative.exercise_date: The option vests on 6/30/2029. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:49 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 147 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003807 · primarydocument.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 Read SEC document |
| July 01, 2019 Filed Apr 11, 2025 20:37 UTC Amendment |
Vessey RupertDirector
|
GrantStock Options (Right to Buy) · Derivative | 588 | $0.00 Strike: $209.26 | $0.00 |
DisclosureSEC source: 0001062993-25-007369 · form4a.xml · derivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588 Underlying: Common Stock · 588 shares Expires 2029-06-30 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:13 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
SaleCommon Stock | 3,117 | $215.00 | $670,155.00 |
DisclosureSEC source: 0001562180-19-003526 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2019. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:30 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $63.03 | $0.00 |
DisclosureSEC source: 0001562180-19-003396 · primarydocument.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:30 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 5,000 | $203.67 | $1,018,345.50 |
DisclosureSEC source: 0001562180-19-003396 · primarydocument.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,526 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.21 to $204.06 , inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:30 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 5,000 | $63.03 | $315,150.00 |
DisclosureSEC source: 0001562180-19-003396 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:29 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,400 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0001562180-19-003162 · primarydocument.xml · derivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:29 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 5,400 | $200.00 | $1,080,000.00 |
DisclosureSEC source: 0001562180-19-003162 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189 Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:29 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 5,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003162 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:14 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $86.25 | $0.00 |
DisclosureSEC source: 0001562180-19-002477 · primarydocument.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:14 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $86.25 | $0.00 |
DisclosureSEC source: 0001562180-19-002477 · primarydocument.xml · derivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:14 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 35,000 | $203.08 | $7,107,681.00 |
DisclosureSEC source: 0001562180-19-002477 · primarydocument.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,382 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.28 to $205.38, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:14 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 35,000 | $86.25 | $3,018,750.00 |
DisclosureSEC source: 0001562180-19-002477 · primarydocument.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
Exercise / conversionRestricted Stock · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-002478 · primarydocument.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
Tax withholdingCommon Stock | 844 | $202.13 | $170,597.72 |
DisclosureSEC source: 0001562180-19-002478 · primarydocument.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823 Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:18 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
Exercise / conversionCommon Stock | 1,667 | $202.13 | $336,950.71 |
DisclosureSEC source: 0001562180-19-002478 · primarydocument.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:07 UTC |
Seth AlpnaDirector
|
GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004308 · primarydocument.xml · derivative · entry 2 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.